Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 17/20 | 0.77 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214235 | 0.94 | AVPR1A (0.71) | AVPR1AEHMT2NPC1MAPTHTT | |
| SCHEMBL5213904 | 0.94 | AVPR1A (0.71) | AVPR1AEHMT2NPC1MAPTHTT | |
| SCHEMBL6187520 | 0.88 | AVPR1A (0.63) | AVPR1AEHMT2NPC1MAPTHTT | |
| SCHEMBL5212353 | 0.88 | AVPR1A (0.82) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5694605 | 0.87 | AVPR1A (0.61) | AVPR1AEHMT2 | |
| SCHEMBL5214851 | 0.87 | AVPR1A (0.81) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5218432 | 0.85 | AVPR1A (1.00) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5215730 | 0.85 | AVPR1A (0.78) | AVPR1ANPC1MAPTHTTRAB9A | |
| SCHEMBL5215652 | 0.84 | AVPR1A (0.55) | AVPR1A | |
| SCHEMBL5212834 | 0.83 | AVPR1A (0.72) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656183-B1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | claimed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | claimed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | claimed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | claimed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1656183-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2006-05-17 | — | — | EP | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050026810-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005006899-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | AVPR1A 104/4885EHMT2 1544/4885NPC1 4756/4885 |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | PTGER2, PTGER1, PTGDR2 | AVPR1A 1068/4885EHMT2 441/4885NPC1 4415/4885 |
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885EHMT2 4856/4885NPC1 2137/4885 |
| US-20080280877-A1 | Azetidines | PTGER2, PTGER1, PTGDR2 | AVPR1A 485/4885EHMT2 1069/4885NPC1 3819/4885 |
| US-20050026810-A1 | Treatment of male sexual dysfunction | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885EHMT2 3321/4885NPC1 2200/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | AVPR1A 67/4885EHMT2 3690/4885NPC1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.